Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome

Clin Endocrinol (Oxf). 2016 Oct;85(4):671-3. doi: 10.1111/cen.13120. Epub 2016 Jun 23.

Authors

Thozhukat Sathyapalan¹, Youssra Dakroury², Lina Ahmed³, Abeer M M Elshewehy³, Eric S Kilpatrick⁴, Anne-Marie Coady⁵, Stephen L Atkin³

Affiliations

¹ Department of Diabetes and Endocrinology, University of Hull, Hull, UK.
² Weill Cornell Medicine Qatar, Doha, Qatar. yhd2001@qatar-med.cornell.edu.
³ Weill Cornell Medicine Qatar, Doha, Qatar.
⁴ Sidra Research Centre, Doha, Qatar.
⁵ Department of Obstetric Ultrasound, Hull & East Yorkshire Women's & Children's Hospital, Hull, UK.

PMID: 27256522
DOI: 10.1111/cen.13120

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Body Mass Index
Cannabinoid Receptor Antagonists / therapeutic use*
Cytokines / blood
Female
Hepatocyte Growth Factor / blood*
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / therapeutic use
Insulin Resistance
Metformin / therapeutic use
Non-alcoholic Fatty Liver Disease / blood
Non-alcoholic Fatty Liver Disease / drug therapy*
Non-alcoholic Fatty Liver Disease / etiology
Obesity / blood
Obesity / complications
Piperidines / therapeutic use*
Polycystic Ovary Syndrome / blood
Polycystic Ovary Syndrome / complications
Polycystic Ovary Syndrome / drug therapy*
Pyrazoles / therapeutic use*
Rimonabant

Substances

Cannabinoid Receptor Antagonists
Cytokines
Hypoglycemic Agents
Insulin
Piperidines
Pyrazoles
Hepatocyte Growth Factor
Metformin
Rimonabant